PMC:7796052 / 550-726 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"16","span":{"begin":145,"end":155},"obj":"Gene"},{"id":"19","span":{"begin":12,"end":22},"obj":"Chemical"},{"id":"20","span":{"begin":126,"end":136},"obj":"Chemical"}],"attributes":[{"id":"A16","pred":"tao:has_database_id","subj":"16","obj":"Gene:3827"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"MESH:D020849"},{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"MESH:D020849"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ntagonists, raloxifene was identified as prospective compound in a virtual screening process. The pharmacodynamics profile of raloxifene towards bradykinin receptors is reporte"}